Literature DB >> 2392793

Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution.

B M Zainudin1, M Biddiscombe, S E Tolfree, M Short, S G Spiro.   

Abstract

The lung dose and deposition patterns of drug delivered by dry powder inhaler are not known. The effects of inhaling 400 micrograms salbutamol delivered by dry powder inhaler (two 200 micrograms salbutamol Rotacaps), by pressurised metered dose inhaler, and by Acorn nebuliser were studied in nine subjects with chronic stable asthma. Technetium-99m labelled Teflon particles were mixed with micronised salbutamol in the pressurised metered dose inhaler and in the capsules; technetium-99m labelled human serum albumin was mixed with the salbutamol solution for the nebuliser study. The pressurised metered dose inhaler deposited 11.2% (SEM 0.8%) of the dose within the lungs; this was significantly more than the dose deposited by the dry powder inhaler (9.1% (0.6%], but did not differ significantly from the dose delivered by the nebuliser (9.9% (0.7%]. Distribution within the peripheral third of the lung was significantly greater with the nebuliser than with the other two systems; FEV1 improved to a significantly greater extent after inhalation of 400 micrograms salbutamol from the pressurised metered dose inhaler (35.6% from baseline) than from the nebuliser (25.8%) or dry powder inhaler (25.2%). Thus after inhalation of similar doses of salbutamol a larger proportion of drug was deposited within the lungs when it was inhaled from a metered dose inhaler than from a dry powder system; the nebuliser achieved the greatest peripheral deposition. The bronchodilator response seems to depend on the amount of drug within the lungs rather than its pattern of distribution.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2392793      PMCID: PMC462532          DOI: 10.1136/thx.45.6.469

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  13 in total

1.  Use of pressurised aerosols by asthmatic patients.

Authors:  I C Paterson; G K Crompton
Journal:  Br Med J       Date:  1976-01-10

2.  Production of 7 mu monodisperse fluorocarbon resin particles tagged with 18F.

Authors:  P Camner; K Philipson; J Svedberg
Journal:  Int J Appl Radiat Isot       Date:  1971-06

3.  Pharmacokinetics of inhaled substances.

Authors:  D S Davies
Journal:  Postgrad Med J       Date:  1975       Impact factor: 2.401

4.  Direct labelling of ipratropium bromide aerosol and its deposition pattern in normal subjects and patients with chronic bronchitis.

Authors:  S G Spiro; C A Singh; S E Tolfree; M R Partridge; M D Short
Journal:  Thorax       Date:  1984-06       Impact factor: 9.139

5.  Problems patients have using pressurized aerosol inhalers.

Authors:  G K Crompton
Journal:  Eur J Respir Dis Suppl       Date:  1982

6.  Survey of the clinical use of pressurized aerosol inhalers.

Authors:  S W Epstein; C P Manning; M J Ashley; P N Corey
Journal:  Can Med Assoc J       Date:  1979-04-07       Impact factor: 8.262

7.  Buccal administration of fenoterol aerosol in young children with asthma.

Authors:  S C Shore; E G Weinberg; M H Dürr
Journal:  S Afr Med J       Date:  1976-08-14

8.  Comparison of salbutamol Rotahaler with conventional pressurized aerosol.

Authors:  M R Hetzel; T J Clark
Journal:  Clin Allergy       Date:  1977-11

9.  Deposition of pressurised aerosols in the human respiratory tract.

Authors:  S P Newman; D Pavia; F Morén; N F Sheahan; S W Clarke
Journal:  Thorax       Date:  1981-01       Impact factor: 9.139

10.  Long-term comparison of salbutamol powder with salbutamol aerosol in asthmatic out-patients.

Authors:  J P Hartley; S G Nogrady; A Seaton
Journal:  Br J Dis Chest       Date:  1979-07
View more
  28 in total

Review 1.  Can lung deposition data act as a surrogate for the clinical response to inhaled asthma drugs?

Authors:  S P Newman
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

Review 2.  Discriminating measures of bronchodilator drug efficacy and potency.

Authors:  H Buck; M Parry-Billings
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

Review 3.  Methods to identify drug deposition in the lungs following inhalation.

Authors:  H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

Review 4.  Aerosol gene therapy.

Authors:  Ajay Gautam; J Clifford Waldrep; Charles L Densmore
Journal:  Mol Biotechnol       Date:  2003-01       Impact factor: 2.695

Review 5.  Inhaler devices for the treatment of asthma and chronic obstructive airways disease (COPD).

Authors:  J Wright; D Brocklebank; F Ram
Journal:  Qual Saf Health Care       Date:  2002-12

6.  Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization.

Authors:  V L Silkstone; S A Corlett; H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

7.  General practitioners and asthma.

Authors:  P W Barritt
Journal:  Thorax       Date:  1992-09       Impact factor: 9.139

8.  Aerosolized bronchodilators.

Authors:  A F Wilson
Journal:  West J Med       Date:  1992-08

9.  How much nebulised budesonide reaches infants and toddlers?

Authors:  K C Lødrup Carlsen; K Nikander; K H Carlsen
Journal:  Arch Dis Child       Date:  1992-09       Impact factor: 3.791

10.  Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta (2 )agonists bronchodilators in asthma.

Authors:  F S Ram; J Wright; D Brocklebank; J E White
Journal:  BMJ       Date:  2001-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.